Platelet Receptor Biology Is Key To Fighting Heart Disease

June 29, 1998

Several weeks ago cardiologists representing 72 organizations from all over the world announced that a new drug called tirofiban -- also known as aggrastat -- could reduce the risk of death in unstable angina patients by 47%. The drug attaches to and blocks biochemical doorways on platelet cells called IIb/IIIa receptors. When bound to these receptors, the drug keeps fibrinogen -- a protein found in the blood -- from adhering to platelets, thereby preventing the formation of platelet thrombi, which can cause arterial blockage.

The lab of Joel Bennett, MD, a professor of medicine, has been working on the molecular biology of the IIb/IIIa receptor for the last 20 years. His lab's discovery of the receptor, its amino acid sequence, and how it works in conjunction with proteins like fibrinogen laid the groundwork for these recent clinical advances. In the last year, Bennett and colleagues have been trying to find out how IIb/IIIa gets activated in the first place. Platelets -- via the IIb/IIIa receptor -- remain inactive until needed.

"So now we're studying the way in which IIb/IIIa goes from an inactive state to an active one to eventually figure out how to inhibit platelet aggregation," says Bennett. "Clinically, any drug that would come out of this would be used in the same way as tirofiban, but may have the potential to be more potent in its anti-thrombotic characteristics."

But here's the rub: To study how IIb/IIIa gets activated presents a challenge because platelets are one of the only cells in the body that don't have nuclei, thereby useless for studies in which genetic manipulation of a protein is necessary. In a paper in the June 12 issue of the Journal of Biological Chemistry, Bennett's team describes a new technique in which they have successfully changed and experimented with IIb/IIIa receptors expressed in b-lymphocytes, circumventing the platelet problem. This is the first step in making the necessary discoveries for the next generation of platelet-based, anti-clotting drugs.

The University of Pennsylvania Medical Center's sponsored research and training ranks third in the United States based on grant support from the National Institutes of Health, the primary funder of biomedical research and training in the nation -- $175 million in federal fiscal year 1997. In addition, for the third consecutive year, the institution posted the highest annual growth in these areas -- 17.6 percent -- of the top ten U.S. academic medical centers.

News releases from the University of Pennsylvania Medical Center are available to reporters by direct e-mail, fax, or U.S. mail, upon request. They are also posted electronically to the medical center's home page,, to EurekAlert!,, an Internet resource sponsored by the American Association for the Advancement of Science, and to the electronic news services SciNews-MedNews and Quadnet.

University of Pennsylvania School of Medicine

Related Platelets Articles from Brightsurf:

Exploring connections between ovarian cancer and blood cells
Recent discoveries made by researchers at Texas A&M University could change the way ovarian cancer is understood and treated.

COVID-19 causes 'hyperactivity' in blood-clotting cells
Changes in blood platelets triggered by COVID-19 could contribute to the onset of heart attacks, strokes, and other serious complications in some patients who have the disease, according to University of Utah Health scientists.

Novel function of platelets in tumor blood vessels found
Scientists at Uppsala University have discovered a hitherto unknown function of blood platelets in cancer.

Platelets exacerbate immune response
Platelets not only play a key role in blood clotting, but can also significantly intensify inflammatory processes.

Blood platelets trigger events that cause organ damage after heart surgery
Damage to kidneys and other organs after heart surgery is not so much triggered by the surgical repair of the heart itself but rather by the massive inflammatory response, which arises from multiple factors: the machinery used to keep blood and oxygen flowing, changes of blood flow during the surgery, and tissue responses to the surgical trauma.

Platelets instead of spheres make screens more economical
ETH scientists have further developed QLED technology for screens. They have produced light sources that for the first time emit high-intensity light in only one direction.

Study: Blood-clotting protein and blood platelets promote immune evasion, cancer progression
A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G.

Blocking platelets: A possible option to prevent fatty liver disease and liver cancer
Blood platelets which interact with liver cells and immune cells play a major role in the development of fatty liver disease, non-alcoholic fatty liver inflammation and liver cancer, scientists from the German Cancer Research Center (DKFZ) in Heidelberg and from Zurich University and University Hospital have now shown in a publication.

Platelet doppelgängers tackle thrombosis and cancer metastasis
Anne-Laure Papa and colleagues have created decoys of platelets -- the body's clot-forming blood cells -- that prevented the formation of dangerous blood clots in vessels (or thrombosis) and combated cancer metastasis in preclinical models.

Researchers develop reversible antiplatelet therapy to fight clotting, cancer metastasis
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer metastasis, according to a study published today in Science Translational Medicine.

Read More: Platelets News and Platelets Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to